Last updated: August 2, 2026
Glycopyrronium tosylate, marketed in the U.S. as Qbrexza, is a topical anticholinergic wipe approved for primary axillary hyperhidrosis in patients aged 9 years and older. Its commercial position is supported by a differentiated, non-systemic delivery format and limited branded competition. Growth is constrained by the narrow indication, insurance coverage variability, patient adherence issues, and the eventual availability of topical generic alternatives.
Qbrexza is marketed in the United States by Journey Medical Corporation following the transfer of commercial rights from Eli Lilly and its Dermira subsidiary. The product has no biosimilar exposure because it is a small-molecule drug, but generic-entry risk remains relevant once applicable formulation and regulatory protections expire.
What is glycopyrronium tosylate and how does Qbrexza work?
Glycopyrronium tosylate is the tosylate salt of glycopyrrolate, an anticholinergic compound. Qbrexza is supplied as a pre-moistened cloth containing glycopyrronium tosylate 2.4% for once-daily topical application to the underarms.
The product reduces sweating by inhibiting acetylcholine activity at eccrine sweat glands. Its commercial differentiation comes from local application rather than oral administration. The product label warns that patients should avoid contact with the eyes and other mucosal surfaces because anticholinergic exposure can produce blurred vision, mydriasis, urinary retention, and other systemic effects.[1]
| Product attribute |
Qbrexza |
| Active ingredient |
Glycopyrronium tosylate |
| Strength |
2.4% |
| Dosage form |
Topical pre-moistened cloth |
| Indication |
Primary axillary hyperhidrosis |
| FDA approval |
June 2018 |
| Initial sponsor |
Dermira, Inc. |
| Current U.S. commercial company |
Journey Medical Corporation |
| Patient population |
Adults and pediatric patients aged 9 years and older |
| Administration |
Once daily |
| Therapeutic category |
Topical anticholinergic |
When did the FDA approve glycopyrronium tosylate?
The FDA approved Qbrexza on June 29, 2018, under New Drug Application 210361. The approval established the first FDA-approved topical anticholinergic cloth specifically indicated for primary axillary hyperhidrosis.[2]
The approval addressed a treatment gap between prescription antiperspirants, oral anticholinergics, botulinum toxin injections, iontophoresis, and surgical interventions. Qbrexza entered a market in which many patients had inadequate control with aluminum chloride products but did not want systemic therapy or procedural treatment.
The FDA approval also expanded the commercial addressable population in 2021 when the label was updated to include children aged 9 years and older.[1] Pediatric eligibility increased the potential patient pool but did not materially change the product’s narrow disease focus.
What is the market size for glycopyrronium tosylate?
There is no widely reported standalone global market category for glycopyrronium tosylate. Commercial analysis generally places Qbrexza within the prescription hyperhidrosis market, which includes topical antiperspirants, oral anticholinergics, botulinum toxin, iontophoresis devices, energy-based procedures, and surgery.
The addressable market has several favorable characteristics:
- Hyperhidrosis is chronic and often begins in adolescence.
- Patients may cycle through multiple treatments.
- Treatment dissatisfaction can support switching.
- A disposable cloth is simpler to use than iontophoresis or injections.
- The pediatric label broadens physician prescribing options.
The market also has structural limitations:
- Primary axillary hyperhidrosis is narrower than generalized or focal hyperhidrosis.
- Many patients use low-cost over-the-counter antiperspirants before seeking prescription care.
- Reimbursement varies by payer and diagnosis coding.
- Anticholinergic adverse effects can limit persistence.
- The product is designed for a single body site and does not address palmar, plantar, craniofacial, or generalized sweating.
Qbrexza therefore has a defensible specialty-pharmaceutical position, but its ceiling is materially below that of drugs treating broad dermatology or primary-care populations.
How has the financial trajectory of Qbrexza developed?
Qbrexza began commercialization under Dermira and was later affected by Dermira’s acquisition by Eli Lilly in 2020. Eli Lilly subsequently transferred U.S. commercial rights to Journey Medical, a dermatology-focused company.[3][4]
The change in ownership altered the product’s commercial strategy. Under a large pharmaceutical company, Qbrexza had access to broader resources but competed for attention against higher-value assets. Under Journey Medical, it became a core dermatology product within a smaller portfolio.
Journey Medical’s public filings identify Qbrexza as one of the company’s principal commercial products. The company has reported revenue growth from its branded dermatology portfolio, although public financial reporting does not always provide a complete, standalone, audited Qbrexza income statement for every period.[5]
| Financial driver |
Effect on Qbrexza |
| Prescription growth |
Positive, particularly among dermatology specialists |
| Pediatric labeling |
Expands prescribing eligibility |
| Insurance coverage |
Can increase access but may require prior authorization |
| Patient copay |
Directly affects refill persistence |
| Sales-force focus |
More important under Journey Medical than under Lilly |
| Manufacturing cost |
Elevated by the specialized cloth delivery system |
| Generic competition |
Long-term negative risk |
| Indication breadth |
Limits maximum revenue potential |
The likely financial trajectory is one of gradual specialty-brand expansion rather than rapid blockbuster growth. Revenue can increase through diagnosis expansion, pediatric adoption, improved payer access, and greater awareness among dermatologists. The principal commercial risk is that the product’s annual treatment cost may be difficult to sustain for patients who view hyperhidrosis as a quality-of-life condition rather than a medically urgent disease.
What patents protect glycopyrronium tosylate and Qbrexza?
Qbrexza’s intellectual-property position is based primarily on patents covering the topical composition, glycopyrronium formulations, and the method of treating hyperhidrosis. The product is not protected only by the active ingredient itself. Glycopyrrolate is an established anticholinergic compound, so commercial protection depends heavily on the specific formulation and use claims.
Publicly associated U.S. patent records include patents assigned to Dermira and related entities covering glycopyrronium topical compositions. One frequently cited patent is U.S. Patent No. 9,999,632, which relates to topical glycopyrronium formulations.[6]
The practical strength of the estate depends on four factors:
- Whether the listed claims cover the generic’s exact concentration and vehicle.
- Whether the generic applicant can design around the cloth, formulation, or dosing claims.
- Whether the Orange Book lists unexpired patents for the approved product.
- Whether patent litigation produces a stay or settlement before approval.
What formulations are protected by Qbrexza patents?
The relevant protection is directed toward topical delivery rather than generic glycopyrrolate as a molecule. Potentially important claim features include:
- Glycopyrronium tosylate concentration.
- Solvent or vehicle composition.
- Cloth or wipe delivery.
- Once-daily application.
- Treatment of primary axillary hyperhidrosis.
- Reduction of sweating with controlled topical exposure.
A generic could attempt to use a different vehicle, package, cloth substrate, concentration, or application format. The commercial question is whether the alternative remains therapeutically equivalent under the FDA’s abbreviated pathway and whether it infringes any formulation or method claims.
What is the Orange Book status of Qbrexza?
Qbrexza is an FDA-approved prescription product listed in the Orange Book under its approved active ingredient and dosage form. The Orange Book is the relevant source for current listed patents, exclusivity information, and therapeutic-equivalence designations.[7]
Regulatory exclusivity associated with the original 2018 approval is no longer the principal barrier to generic entry. The remaining protection is primarily patent-based. Because Orange Book listings and expiration calculations can change through patent corrections, pediatric extensions, terminal disclaimers, or regulatory updates, the current FDA listing controls the operative analysis.
The product does not have biologic exclusivity and is not subject to the biosimilar pathway. A competitor would pursue an abbreviated new drug application, not an abbreviated biosimilar application.
When does glycopyrronium tosylate lose exclusivity?
Qbrexza’s effective loss-of-exclusivity date depends on the latest enforceable Orange Book-listed patent and any applicable pediatric extension. The active ingredient has no meaningful composition-of-matter exclusivity because glycopyrrolate is an established compound.
The key timing distinction is:
| Protection type |
Commercial significance |
| New drug exclusivity |
Largely elapsed for the 2018 approval |
| Pediatric exclusivity |
May extend qualifying listed protection by six months |
| Formulation patents |
Main potential barrier to generic entry |
| Method-of-use patents |
Relevant if the generic label includes the protected indication |
| Device or packaging claims |
May be less effective if a generic uses a different delivery system |
| Trade secrets |
Can protect manufacturing processes but do not block an independently developed generic |
The most important risk period is the point at which an ANDA applicant can certify that listed patents are invalid, unenforceable, or not infringed. That certification can trigger Paragraph IV litigation.
Which companies are challenging glycopyrronium tosylate?
Publicly visible generic competition is the main long-term threat, but the commercial record does not establish a major approved generic equivalent to Qbrexza. A Paragraph IV challenge would normally become visible through patent litigation, FDA litigation reporting, or a notice-letter disclosure by the brand company.
Potential entrants would likely include large generic manufacturers with dermatology portfolios and contract development organizations capable of producing topical wipes. The technical barrier is higher than for a simple tablet because the competitor must reproduce or establish equivalence for the drug, vehicle, cloth, packaging, and application characteristics.
No biosimilar company is relevant to Qbrexza. The product is a small molecule, not a monoclonal antibody, peptide biologic, or other biological product.
What patent litigation and settlements affect Qbrexza?
The commercial record does not indicate a major public patent settlement that has materially reset Qbrexza’s generic-entry date. If a Paragraph IV case is filed, the principal issues would likely include:
- Written-description and enablement of topical formulation claims.
- Obviousness based on prior glycopyrrolate formulations.
- Infringement by a non-cloth or modified-cloth product.
- Whether method-of-use claims are enforceable against a skinny-label generic.
- The scope of any 30-month FDA approval stay.
A settlement could permit an authorized generic, a delayed generic launch, or entry before full patent expiry. Without a disclosed settlement, the base commercial assumption is continued branded sales until a successful generic applicant obtains FDA approval and clears enforceable patent barriers.
How strong is the glycopyrronium tosylate patent estate?
The estate is moderately strong from a product-differentiation standpoint but less secure than a composition-of-matter estate.
Its strengths are the specialized dosage form, the topical route, the defined concentration, and the clinical use in axillary hyperhidrosis. Its weaknesses are the age of the active compound, the predictable nature of anticholinergic therapy, and the possibility of designing around the cloth or vehicle.
The estate is strongest against a close copy of Qbrexza. It is weaker against a materially different topical glycopyrronium product that demonstrates bioequivalence or therapeutic equivalence through a different delivery system.
How does Qbrexza compare with competing hyperhidrosis treatments?
| Treatment |
Main advantage |
Main limitation |
Competitive effect on Qbrexza |
| Aluminum chloride |
Low cost and familiar |
Irritation and limited efficacy |
Strong first-line alternative |
| Oral glycopyrrolate |
Can treat multiple body areas |
Systemic anticholinergic effects |
Competes in severe disease |
| Oxybutynin |
Oral efficacy and low cost |
Systemic adverse effects |
Competes where topical therapy fails |
| Botulinum toxin |
High efficacy and durable response |
Injections, cost, procedure burden |
Competes in refractory axillary disease |
| Iontophoresis |
Useful for palms and feet |
Equipment and repeated treatment |
Limited direct overlap |
| Qbrexza |
Prescription topical format and non-procedural use |
Local and systemic anticholinergic effects; cost |
Differentiated middle-ground option |
Qbrexza’s strategic position is strongest in patients who want more efficacy than antiperspirants but want to avoid oral therapy or injections.
What generic launch risks exist for Qbrexza?
The most likely generic launch scenarios are:
- A close topical copy challenges formulation patents through Paragraph IV certification.
- A non-cloth topical product seeks approval using a different delivery system.
- An applicant initially uses a skinny label that omits patented methods of use.
- An authorized generic launches through a brand-company agreement.
- A formulation patent survives, delaying entry until its expiration.
Generic erosion would likely affect price before it eliminates branded demand. Dermatologists may continue prescribing Qbrexza for patients who prefer the established cloth format, while payers shift volume toward lower-cost alternatives.
What is the geographic coverage of glycopyrronium tosylate?
Qbrexza’s principal commercial footprint has been the United States. The U.S. market is supported by FDA approval, established dermatology distribution, and the product’s first-mover status in topical prescription treatment.
International expansion is constrained by:
- Separate regulatory requirements.
- Country-specific hyperhidrosis diagnosis and reimbursement practices.
- Local patent status.
- Limited market size in some jurisdictions.
- The need for regional commercial partners.
A global opportunity would require licensing or distribution arrangements, but public disclosures do not establish a major international licensing platform comparable to a multinational dermatology franchise.
What manufacturing and intellectual-property barriers affect Qbrexza?
Manufacturing is more complex than for a conventional tablet. The product requires drug loading or impregnation of a disposable cloth, stability control, packaging that preserves dose uniformity, and a reproducible application profile.
Manufacturing know-how can increase switching costs for competitors, but it is not equivalent to patent exclusivity. A generic company can develop an alternative process if it can meet FDA quality and equivalence requirements.
The strongest barriers are likely the combined technical requirements of topical formulation, cloth uniformity, packaging, and clinical or pharmacokinetic equivalence. These barriers may slow entry without preventing it.
Key Takeaways
- Glycopyrronium tosylate is marketed as Qbrexza for primary axillary hyperhidrosis.
- FDA approval occurred in June 2018, with pediatric labeling expanded to patients aged 9 and older.
- Journey Medical is the current U.S. commercial company after rights moved from Dermira and Eli Lilly.
- The product has a differentiated topical cloth format but a narrow therapeutic market.
- Revenue growth depends on diagnosis, payer access, pediatric adoption, and refill persistence.
- The active ingredient is old, so protection depends mainly on formulation, delivery, and method-of-use patents.
- Qbrexza faces generic risk, not biosimilar risk.
- The patent estate is stronger against a close copy than against a redesigned topical product.
- Public information does not establish a major generic settlement that has reset the product’s entry timeline.
- Manufacturing complexity may delay generic entry but is unlikely to prevent eventual competition.
FAQs About Glycopyrronium Tosylate
Is glycopyrronium tosylate the same as glycopyrrolate?
Glycopyrronium tosylate is a salt form of glycopyrrolate. Qbrexza uses glycopyrronium tosylate in a topical 2.4% cloth formulation.
Is Qbrexza a biologic drug?
No. Qbrexza is a small-molecule drug and would face an ANDA-based generic pathway rather than biosimilar competition.
Can glycopyrronium tosylate treat excessive sweating on the hands or feet?
Qbrexza is FDA-approved for primary axillary hyperhidrosis. Use on other body sites may involve different safety, efficacy, and regulatory considerations.
Who owns the Qbrexza brand?
Journey Medical Corporation is the U.S. commercial company associated with Qbrexza. The product originated with Dermira, which was acquired by Eli Lilly.
What is the main commercial threat to Qbrexza?
The main threat is a lower-priced topical generic that demonstrates equivalence through a similar cloth or an alternative delivery system. Oral anticholinergics, botulinum toxin, and low-cost antiperspirants remain important competitive substitutes.
References
- U.S. Food and Drug Administration. (2024). Qbrexza (glycopyrronium) cloth, 2.4% prescribing information.
- U.S. Food and Drug Administration. (2018). FDA approves first treatment specifically for excessive underarm sweating.
- Eli Lilly and Company. (2020). Lilly to acquire Dermira.
- Journey Medical Corporation. (2022). Journey Medical acquires U.S. rights to Qbrexza.
- Journey Medical Corporation. (2024). Annual report and financial statements.
- U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,999,632, topical glycopyrronium formulations.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
